Anti-angiogenic drugs, on the other hand, reverse VEGF-mediated immunosuppression by enhancing the killing capacity of cancer cells by T-cell-mediated checkpoint inhibitors and re-sensitizing this subset of tumors to PD-L1 inhibitors (17, 18). The gene discussed is CD274; the disease is cancer.